Vantictumab is a human IgG2 monoclonal antibody designed for the treatment of

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

. This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with

Bayer Bayer AG (, commonly pronounced ; ) is a German multinational corporation, multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of busi ...

. OncoMed was awarded a patent in 2016, which is set to expire in 2029. In April 2017, Bayer terminated its option to license vantictumab. It inhibits wnt signalling by targeting the frizzled receptors on cancer cells. Phase I trials have been completed for

pancreatic cancer Pancreatic cancer arises when cell (biology), cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a Neoplasm, mass. These cancerous cells have the malignant, ability to invade other parts of t ...

, non-small cell lung cancer, and

breast cancer Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a re ...

. In 2016 results were reported from a phase 1b clinical trial for

triple-negative breast cancer Triple-negative breast cancer (TNBC) is any breast cancer that lacks or show low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tum ...

and in 2020 for pancreatic cancer.

References

Monoclonal antibodies for tumors Experimental cancer drugs {{monoclonal-antibody-stub